Eli Lilly and Company
COMBINATION OF RAMUCIRUMAB AND MERESTINIB FOR USE IN TREATMENT OF COLORECTAL CANCER

Abstract:

The present disclosure relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and merestinib, or a pharmaceutically acceptable salt thereof, and to methods of using the combination to treat certain disorders, such as colorectal cancer, including advanced or metastatic colorectal cancer and/or local colorectal cancer.